Celldex Therapeutics (NASDAQ:CLDX) Issues Earnings Results, Beats Estimates By $0.12 EPS

Key Points

• Celldex Therapeutics beat EPS expectations, reporting a quarterly loss of $0.94 per share versus the consensus estimate of a $1.06 loss. Revenue was just $0.02 million, below analysts’ $0.73 million forecast.
• Shares rose to $41.71, near the company’s 52-week high of $42.92, while the stock’s 50-day and 200-day moving averages stood at $35.19 and $31.54, respectively.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and a $55.46 price target; recent targets include $53 from Barclays and $72 from Wells Fargo.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.94) earnings per share for the quarter, beating the consensus estimate of ($1.06) by $0.12, FiscalAI reports. The firm had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.73 million.

Celldex Therapeutics Price Performance

Shares of NASDAQ:CLDX traded up $0.15 during trading on Friday, hitting $41.71. The company had a trading volume of 808,912 shares, compared to its average volume of 954,386. The stock has a market cap of $3.27 billion, a price-to-earnings ratio of -9.59 and a beta of 0.87. The company has a fifty day simple moving average of $35.19 and a two-hundred day simple moving average of $31.54. Celldex Therapeutics has a one year low of $19.72 and a one year high of $42.92.

Institutional Trading of Celldex Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of CLDX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Celldex Therapeutics by 1.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company's stock worth $798,000 after buying an additional 680 shares during the period. Millennium Management LLC lifted its holdings in shares of Celldex Therapeutics by 327.3% in the 1st quarter. Millennium Management LLC now owns 399,932 shares of the biopharmaceutical company's stock worth $7,259,000 after acquiring an additional 306,330 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Celldex Therapeutics by 12.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 131,296 shares of the biopharmaceutical company's stock worth $2,383,000 after acquiring an additional 14,979 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Celldex Therapeutics by 27.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company's stock worth $47,000 after purchasing an additional 501 shares during the period. Finally, Hsbc Holdings PLC bought a new position in Celldex Therapeutics during the 2nd quarter valued at about $347,000.

Analyst Ratings Changes

A number of research analysts have recently commented on CLDX shares. Barclays increased their target price on Celldex Therapeutics from $48.00 to $53.00 and gave the company an "overweight" rating in a research report on Friday. HC Wainwright restated a "buy" rating and issued a $42.00 price target on shares of Celldex Therapeutics in a research report on Monday, June 15th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Celldex Therapeutics in a research note on Friday, July 17th. UBS Group increased their price objective on shares of Celldex Therapeutics from $38.00 to $45.00 and gave the company a "buy" rating in a research report on Wednesday, June 10th. Finally, Wells Fargo & Company lifted their price objective on shares of Celldex Therapeutics from $48.00 to $72.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $55.46.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company's research platforms leverage novel antibody and vaccine technologies designed to engage the patient's immune system, with a particular emphasis on oncology and neurologic indications. Celldex's pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex's lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source